Trial Profile
Prospective Observational Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (APPROPRIATE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms APPROPIATE; APPROPRIATE
- Sponsors Amgen; Celgene Corporation
- 18 Dec 2020 Status changed from active, no longer recruiting to completed.
- 24 Sep 2020 Planned End Date changed from 25 Aug 2020 to 31 Oct 2020.
- 24 Sep 2020 Status changed from recruiting to active, no longer recruiting.